Artificial Intelligence in Health Care and Drug Discovery for Hepatitis.

Abstract

Hepatitis is a viral disease which represents a major damage to public health and it globally leads to cause of death. Hepatitis is classified into five specific types – Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Hepatitis D virus, Hepatitis E virus. Each type has specific differences like transmission, risk, pathophysiology, complications, etc. In 2016, the WHO released its plan to eliminate viral hepatitis as a public health threat by the year 2030, along with a discussion of current gaps and prospects for both regional and global eradication of viral hepatitis. AI offers hope and promises to use improved diagnosis for treatment strategies. Advances in Artificial Intelligence have created new opportunities to improve the prevention detection, diagnosis, treatment and monitoring of hepatitis across different health care settings. AI techniques, including machine learning, deep learning and natural language processing can rapidly evaluate diverse sources of medical information such as electronic health records, biochemical investigation, radiological images, pathology findings and viral genomic data. These technologies assist in identifying infected individuals, assessing the extent of liver injury, predicting fibrosis progression, estimating the likelihood of treatment success and recognising patients who have increased risk of serious complications. Further most AI contributes to public health by improving hepatitis surveillance, enhancing large scale screening program, identifying vulnerable populations and supporting timely preventing interventions.